{
  "id": "58ce5c7c1f5fb2b734000001",
  "type": "list",
  "question": "List metalloenzyme inhibitors.",
  "ideal_answer": "Foscarnet\nVT-1129\nVT-1161 \nBB-3497\nhydroxamate molecules\nsiderophores",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/19949750",
    "http://www.ncbi.nlm.nih.gov/pubmed/21046516",
    "http://www.ncbi.nlm.nih.gov/pubmed/21189019",
    "http://www.ncbi.nlm.nih.gov/pubmed/11551755",
    "http://www.ncbi.nlm.nih.gov/pubmed/22308350",
    "http://www.ncbi.nlm.nih.gov/pubmed/17314045",
    "http://www.ncbi.nlm.nih.gov/pubmed/18666306",
    "http://www.ncbi.nlm.nih.gov/pubmed/24074025"
  ],
  "snippets": [
    {
      "text": " Clinically approved inhibitors were selected as well as several other reported metalloprotein inhibitors in order to represent a broad range of metal binding groups (MBGs), including hydroxamic acid, carboxylate, hydroxypyridinonate, thiol, and N-hydroxyurea functional groups.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24074025",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "A total of 21 different raltegravir-chelator derivative (RCD) compounds were prepared that differed only in the nature of the MBG. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22308350",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "At least two compounds (RCD-4, RCD-5) containing a hydroxypyrone MBG were found to display superior strand-transfer inhibition when compared to an abbreviated analogue of raltegravir (RCD-1). ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22308350",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "By screening a library of metalloenzyme inhibitors, the N-formyl-hydroxylamine derivative BB-3497 was identified as a potent inhibitor of Escherichia coli peptide deformylase with antibacterial activity both in vitro and in vivo.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/11551755",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " The 8-hydroxyquinoline represents a promising new chelator scaffold for the development of MMP inhibitors that was discovered by use of a metalloprotein-focused chelator fragment library.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21189019",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " the metalloenzyme inhibitors VT-1129 and VT-1161 (both Viamet Pharmaceuticals)",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21046516",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Based on their ability to chelate metals, hydroxamate molecules and siderophores have been successfully used as metalloenzyme inhibitors.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19949750",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " Using this model, we identified two nitrogen donor compounds--2,2'-dipyridylamine (DPA) and triazacyclononane (TACN)--as the most selective ZBGs for zinc metalloenzyme inhibitor development. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/18666306",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Foscarnet (phosphonoformate trisodium salt), an antiviral used for the treatment of HIV and herpes virus infections, also acts as an activator or inhibitor of the metalloenzyme carbonic anhydrase (CA, EC 4.2.1.1)",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/17314045",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "VT-1129, VT-1161, BB-3497, hydroxamate molecules, siderophores, Foscarnet"
}